UBS Group reaffirmed their neutral rating on shares of Sanofi (NYSE:SNY) in a research note released on Monday, www.boersen-zeitung.de reports.
Several other equities research analysts have also recently weighed in on the stock. JPMorgan Chase & Co. restated a neutral rating on shares of Sanofi in a research report on Thursday, January 11th. Nord/LB restated a neutral rating on shares of Sanofi in a research report on Tuesday, January 2nd. Cowen set a $48.00 price objective on shares of Sanofi and gave the company a hold rating in a research report on Monday, December 18th. Bank of America cut shares of Sanofi from a buy rating to a neutral rating in a research report on Wednesday, December 6th. Finally, Morgan Stanley cut shares of Sanofi from an overweight rating to an underweight rating in a research report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $51.50.
Shares of Sanofi (NYSE SNY) opened at $44.60 on Monday. Sanofi has a 1 year low of $39.42 and a 1 year high of $50.65. The firm has a market cap of $113,200.00, a price-to-earnings ratio of 20.18, a P/E/G ratio of 2.58 and a beta of 0.86. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Thursday, November 2nd. The company reported $1.00 earnings per share for the quarter, hitting the consensus estimate of $1.00. Sanofi had a net margin of 25.44% and a return on equity of 25.19%. analysts forecast that Sanofi will post 3.3 EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of SNY. BlackRock Inc. increased its position in Sanofi by 47.6% during the second quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock valued at $107,100,000 after acquiring an additional 720,523 shares during the last quarter. Investment Centers of America Inc. bought a new position in Sanofi during the second quarter valued at $300,000. Strategic Global Advisors LLC increased its position in Sanofi by 0.6% during the second quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock valued at $414,000 after acquiring an additional 54 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in Sanofi by 22.7% during the second quarter. UBS Asset Management Americas Inc. now owns 75,475 shares of the company’s stock valued at $3,616,000 after acquiring an additional 13,959 shares during the last quarter. Finally, FMR LLC increased its position in Sanofi by 3.0% during the second quarter. FMR LLC now owns 5,374,385 shares of the company’s stock valued at $257,487,000 after acquiring an additional 155,751 shares during the last quarter. Institutional investors and hedge funds own 9.08% of the company’s stock.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.